| LncRNA |
Compound |
Cancer |
P-value |
Effect |
| ENSG00000232160.2 |
ABT-263 (navitoclax) |
Bladder urothelial carcinoma |
0.031280605 |
Resistant |
| ENSG00000232160.2 |
ABT-263 (navitoclax) |
Chronic Lymphocytic Leukemia |
0.024238216 |
Resistant |
| ENSG00000232160.2 |
ABT-263 (navitoclax) |
Sarcoma |
0.006045127 |
Sensitive |
